Increased soluble C5b-9 in CSF of neuromyelitis optica

Scandinavian Journal of Immunology

Volumn 79, Issue 2, 2014, Pages 127-130

  Wang, H ^a,b   Wang, K ^a   Wang, C ^a   Qiu, W ^b   Lu, Z ^b   Hu, X ^b  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT MEMBRANE ATTACK COMPLEX; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C5A; SC5B 9 PROTEIN COMPLEX; SC5B-9 PROTEIN COMPLEX;

ADULT; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID LEVEL; CERVICAL SPONDYLOSIS; CLINICAL FEATURE; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; HUMORAL IMMUNITY; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; NEUROLOGIC DISEASE; PRIORITY JOURNAL; SHY DRAGER SYNDROME; DISABILITY; IMMUNOLOGY; MIDDLE AGED;

ADULT; COMPLEMENT C3A; COMPLEMENT C5A; COMPLEMENT MEMBRANE ATTACK COMPLEX; DISABILITY EVALUATION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROMYELITIS OPTICA;

EID: 84897019540     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/sji.12132     Document Type: Article

References (31)

1. Jadidi-Niaragh F, Mirshafiey A. Th17 cell, the new player of neuroinflammatory process in multiple sclerosis. Scand J Immunol 2011;74:1-13.
2. Kira J. Neuromyelitis optica and asian phenotype of multiple sclerosis. Ann N Y Acad Sci 2008;142:58-71.
3. Holmøy T, Vartdal F. The immunological basis for treatment of multiple sclerosis. Scand J Immunol 2007;66:374-82.
4. Lennon VA, Wingerchuk DM, Kryzer TJ et al. A serum auto-antibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004;364:2106-12.
5. Correale J, Fiol M. Activation of humoral immunity and eosinophils in neuromyelitis optica. Neurology 2004;63:2363-70.
6. Kawachi I. Humoral and cellular immune responses in neuromyelitis optica. Rinsho Shinkeigaku 2010;50:873-4.
7. Wang H, Wang K, Zhong X et al. Cerebrospinal fluid BAFF and APRIL levels in neuromyelitis optica and multiple sclerosis patients during relapse. J Clin Immunol 2012;32:1007-11.
8. Lucchinetti CF, Mandler RN, McGavern D et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 2002;125:1450-61.
9. Wingerchuk DM. Neuromyelitis optica: potential roles for intravenous immunoglobulin. J Clin Immunol 2013;33:S33-7.
10. Mollnes TE, Vandvik B, Lea T, Vartdal F. Intrathecal complement activation in neurological diseases evaluated by analysis of the terminal complement complex. J Neurol Sci 1987;78:17-28.
11. Sanders ME, Alexander EL, Koski CL et al. Terminal complement complexes (SC5b-9) in cerebrospinal fluid in autoimmune nervous system diseases. Ann N Y Acad Sci 1988;540:387-8.
12. Sellebjerg F, Jaliashvili I, Christiansen M, Garred P. Intrat;hecal activation of the complement system and disability in multiple sclerosis. J Neurol Sci 1998;157:168-74.
13. Rus H, Cudrici C, Niculescu F, Shin ML. Complement activation in autoimmune demyelination: dual role in neuroinflammation and neuroprotection. J Neuroimmunol 2006;180:9-16.
14. Doi H, Matsushita T, Isobe N et al. Hypercomplementemia at relapse in patients with anti-aquaporin-4 antibody. Mult Scler 2009;15:304-10.
15. Tüzün E, Kürtüncü M, Türkoğlu R et al. Enhanced complement consumption in neuromyelitis optica and Behçet's disease patients. J Neuroimmunol 2011;233:211-5.
16. Chen Y, Li R, Wu AM, Shu YQ, Lu ZQ, Hu XQ. The complement and immunoglobulin levels in NMO patients. Neurol Sci 2013; PubMed PMID: 23881468 [Epub ahead of print].
17. Kuroda H, Fujihara K, Takano R et al. Increase of complement fragment C5a in cerebrospinal fluid during exacerbation of neuromyelitis optica. J Neuroimmunol 2013;254:178-82.
18. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006;66:1485-9.
19. Polman CH, Reingold SC, Banwell B et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69:292-302.
20. Misu T, Fujihara K, Kakita A et al. Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain 2007;130:1224-34.
21. Linhares UC, Schiavoni PB, Barros PO et al. The ex vivo production of IL-6 and IL-21 by CD4+ T cells is directly associated with neurological disability in neuromyelitis optica patients. J Clin Immunol 2013;33:179-89.
22. Bhakdi S, Hugo F, Tranum-Jensen J. Functions and relevance of the terminal complement sequence. Blut 1990;60:309-18.
23. Rinder CS, Rinder HM, Smith MJ et al. Selective blockade of membrane attack complex formation during simulated extracorporeal circulation inhibits platelet but not leukocyte activation. J Thorac Cardiovasc Surg 1999;118:460-6.
24. Weiszhár Z, Bikov A, Gálffy G et al. Elevated complement factor H levels in asthmatic sputa. J Clin Immunol 2013;33:496-505.
25. Chiu YY, Nisihara RM, Würzner R, Kirschfink M, de Messias-Reason IJ. SC5b-9 is the most sensitive marker in assessing disease activity in Brazilian SLE patients. J Investig Allergol Clin Immunol 1998;8:239-44.
26. Corallini F, Bossi F, Gonelli A et al. The soluble terminal complement complex (SC5b-9) up-regulates osteoprotegerin expression and release by endothelial cells: implications in rheumatoid arthritis. Rheumatology (Oxford) 2009;48:293-8.
27. Saadoun S, Waters P, Bell BA, Vincent A, Verkman AS, Papadopoulos MC. Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain 2010;133:349-61.
28. Hinson SR, McKeon A, Fryer JP, Apiwattanakul M, Lennon VA, Pittock SJ. Prediction of neuromyelitis optica attack severity by quantitation of complement-mediated injury to aquaporin-4-expressing cells. Arch Neurol 2009;66:164-1167.
29. Sabater L, Giralt A, Boronat A et al. Cytotoxic effect of neuromyelitis optica antibody (NMO-IgG) to astrocytes: an in vitro study. J Neuroimmunol 2009;215:31-5.
30. Sellebjerg F, Christiansen M, Garred P. MBP, anti-MBP and anti-PLP antibodies, and intrathecal complement activation in multiple sclerosis. Mult Scler 1998;4:127-31.
31. Tegla CA, Cudrici C, Rus V et al. Neuroprotective effects of the complement terminal pathway during demyelination: implications for oligodendrocyte survival. J Neuroimmunol 2009;213:3-11.